Welcome to our dedicated page for Belite Bio news (Ticker: BLTE), a resource for investors and traders seeking the latest updates and insights on Belite Bio stock.
Belite Bio, Inc. reports clinical and regulatory developments for tinlarebant, an oral investigational therapy for degenerative retinal diseases. The company focuses on Stargardt disease type 1 (STGD1) and geographic atrophy in advanced dry age-related macular degeneration, with a program designed to reduce accumulation of bisretinoid toxins in the eye.
Recurring updates include DRAGON and DRAGON II Stargardt disease studies, PHOENIX geographic atrophy development, FDA interactions, scientific meeting presentations, investor-conference appearances, financial results, annual Form 20-F availability, and capital actions involving American Depositary Shares. Company news also covers corporate updates for a foreign private issuer whose securities trade under BLTE.
Belite Bio (NASDAQ: BLTE) reported unaudited Q1 2026 results and key clinical milestones. The company initiated a rolling NDA submission to the FDA for tinlarebant in STGD1, targeting completion in Q2 2026, and completed hiring of key commercial leadership as commercialization preparation advances.
Phase 3 DRAGON in adolescent STGD1 is completed, while DRAGON II and pivotal GA PHOENIX trials have finished enrollment. As of March 31, 2026, Belite Bio held $276.4M in cash and $522.2M in U.S. treasuries, and recorded a GAAP net loss of $26.9M.
Belite Bio (NASDAQ: BLTE) received orphan drug status from Swissmedic for tinlarebant in Stargardt disease (STGD1). Tinlarebant met the primary endpoint in the global Phase 3 DRAGON trial, showing a 35.7% reduction in retinal lesion growth versus placebo. A rolling NDA submission to the FDA is underway, with completion expected in 2Q 2026. Tinlarebant also holds Breakthrough Therapy, Fast Track, Rare Pediatric Disease, and Orphan Drug designations in major markets.
Belite Bio (NASDAQ: BLTE) will deliver an oral presentation at the 27th Fundus Disease Forum and International Retinal Symposium (Retina China 2026) in Nanjing on May 22, 2026.
The talk will highlight previously disclosed Phase 3 DRAGON trial topline results for tinlarebant in adolescent Stargardt disease type 1, including a 35.7% reduction in atrophic retinal lesion growth versus placebo and a generally well tolerated safety profile.
Belite Bio (NASDAQ: BLTE) will host a webcast on May 20, 2026 at 4:30 p.m. ET to discuss first quarter 2026 financial results and provide a business update. Investors can access the live webcast and a 90-day replay via the company’s investor relations website.
Belite Bio (NASDAQ: BLTE) will give an oral presentation on May 1, 2026 at the Retinal Therapeutics Innovation Summit in Denver covering topline Phase 3 DRAGON results for tinlarebant in Stargardt disease type 1.
According to the company, tinlarebant showed a 35.7% reduction in atrophic retinal lesion growth versus placebo and demonstrated a strong safety profile. Presentation details: May 1, 2026, 10:55-11:10 a.m. MDT, session "Small Molecules to the Rescue," presenter Nathan L. Mata, Ph.D.
Belite Bio (NASDAQ: BLTE) will participate in four investor conferences between April 28 and May 26, 2026, including Deutsche Bank ADR Virtual, BofA Securities Health Care, H.C. Wainwright BioConnect Nasdaq, and Stifel Virtual Ophthalmology Forum.
Webcasts are available under Events on the company investor site and replays will be archived for 90 days after each presentation.
Belite Bio (NASDAQ: BLTE) has initiated a rolling submission of a New Drug Application to the FDA for tinlarebant, an investigational oral therapy for Stargardt disease type 1 (STGD1). The FDA previously granted Breakthrough Therapy Designation and approved the rolling submission.
The company expects to complete the NDA rolling submission in the second quarter of 2026 and cites transformative Phase 3 DRAGON results; Belite is preparing commercialization teams for a potential launch next year, contingent on regulatory review.
Belite Bio (NASDAQ: BLTE) announced that its annual report on Form 20-F, containing audited consolidated financial statements for the year ended December 31, 2025, was filed with the SEC on March 31, 2026 and is available on the company website.
Shareholders may request a free hard copy of the annual report. The notice was issued pursuant to Nasdaq Listing Rule 5250(d)(1)(C).
Belite Bio (NASDAQ: BLTE) will participate in a fireside chat at the Leerink Global Healthcare Conference on Monday, March 9, 2026 at 1:00 pm ET. A live webcast is available via the company's investor relations Events page, with replays archived for 90 days.
Belite Bio (NASDAQ: BLTE) reported positive pivotal Phase 3 DRAGON topline results showing a 35.7% reduction in macular lesion growth versus placebo and remains on track to submit an NDA to the FDA in Q2 2026. The company completed a $402 million public offering and entered 2026 with $352.9M cash and $419.7M investments.
Other updates: DRAGON II reached targeted enrollment (72 subjects as of Feb 27, 2026), PHOENIX completed enrollment with 530 subjects, and GAAP net loss for 2025 was $77.6M.